Lenalidomide HCl (formerly CC-5013; CC 5013; IMiD1; trade name Revlimid), the hydrochloride salt of Lenalidomide, is a derivative of thalidomide approved for use in the United States since 2005 in the treatment for myeloma and blood disorders called myelodysplastic syndromes. Lenalidomide acts as an immunomodulatory drug with a variety of biological effects such as anticancer, anti-angiogenic, and anti-inflammatory properties.

纯度：≥98%

CAS：1243329-97-6